Recruiting
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread - CA017-003
Updated: 24 January, 2020 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
For more information regarding Bristol-Myers Squibb (BMS) Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - During dose escalation, subjects with advanced solid tumors that have progressed following at least one standard regimen - During cohort expansion, subjects with advanced cancer that either have received at least one prior therapy or are treatment naive, depending on the specified tumor type - Subjects must have measurable disease - Subject must consent to provide previously collected tumor tissue and a tumor biopsy during screening. - At least 4 weeks since any previous treatment for cancer - Must be able to swallow pills or capsules - Eastern Cooperative Oncology Group(ECOG) Performance Status 0-1 Exclusion Criteria: - Active or chronic autoimmune diseases - Uncontrolled or significant cardiovascular disease - History of any chronic Hepatitis, active Hepatitis B or C, human immunodeficiency virus (HIV), or acquired immune deficiency syndrome (AIDS) - Chronic hepatitis: Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except for subjects with hepatocellular carcinoma) - Active central nervous system (CNS) metastases and CNS metastases as the only sites of disease - Active infection Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
